




# Life Sciences Financing Summary Europe

April 2016

January 2016 saw a large amount of private financing with an aggregate value of EUR 390m raised by 10 European Biotech companies (Therapeutics & Diagnostics), representing the 3<sup>rd</sup> largest amount of the past 12 months, behind only April and July 2015. Although February saw a smaller total amount raised - EUR 122m - the average round was the second largest of the study period, at EUR 39m, behind only that of April 2015, and EUR 8m, or 26%, larger than the average in July 2015.

The largest capital increase in Life Sciences was by Prothena Corporation plc with EUR 102.9m, whose most advanced product is in Phase III clinical trials. This is the second capital increase by Prothena Corporation plc with the first one taking place in April 2015, which was of EUR 116m.

The largest private financing round for European Therapeutics & Diagnostics companies in January and February 2016 was the CHF 60m (EUR 54.9m) raised in February by Cardioentis AG. Continue reading below to learn more about the financing highlights of January and February 2016 in the European Life Science industry.



Source: Biotechgate.com

\*The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.



## Selected financing highlights: companies raising funds

February 2016

### ENYO Pharma announces closing of a EUR 22m Series A financing round

Lyon, France - ENYO Pharma, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, announced on the 3<sup>rd</sup> of February 2016 that it has secured a EUR 22m Series A financing round. The investment is intended to help the company roll out its clinical hepatitis-B programme more quickly.

The deal was led by Sofinnova Partners, alongside Morningside and Bpifrance via its fund InnoBio, and should enable ENYO Pharma to conduct Phase I trials in the first half of 2016, and Phase II trials on chronic hepatitis B sufferers should follow by 2017.

*(Source: press release)*

January 2016

### Cardiorentis AG Raises EUR 54.9m in Series B Financing

ZUG, Switzerland - Cardiorentis AG, a privately held biopharmaceutical company, announced on the 10<sup>th</sup> of January 2016 that it has raised EUR 54.9m in a Series B financing. Led by three new private investors, the equity financing will support the commercial build-out of Ularitide, the company's Phase III treatment for acute decompensated heart failure (ADHF), including upcoming regulatory submissions expected in the second half of 2016.

*(Source: press release)*



## Selected financing highlights – investors in January, February 2016

The following investors have made investments into European Life Science companies during January and February 2016:

- Aravis Venture Fund
- Aurum Ventures
- BZ Bank
- Bayern Kapital
- Entrepreneurs Fund
- InnoBio
- Fort Rock Capital.
- Hanseatic Asset Management LBG
- Heidelberg Capital Private Equity
- Morningside Ventures
- Pictet Private Equity Fund
- Rosetta Capital
- Shavit Capital
- Sofinnova Partners




## Quarterly Biotech Equity Financing Breakdown by Lead Product Development Phase (Therapeutics & Diagnostics)

With the end of the year, we saw that Q4 2015 was dominated by private investments in companies with lead products in Phase I development (43% of total financing) and Phase II development (43% of total financing). We also saw a marked difference from previous quarters with no financing in companies with lead products in Phase III development.

For the full year 2015, we saw highest proportion of financing rounds going into companies with lead products in Phase II development, with an average of 39% of total financing rounds.

**Financing by Lead Product Development Phase**



Source: Biotechgate.com

\*The graph above shows the proportion of financing rounds by lead product development phase in the therapeutics and diagnostics category per quarter. All units are in EUR and include only private companies

## January, February 2016 financing rounds summary

Source: Biotechgate – [www.biotechgate.com](http://www.biotechgate.com)

Company Name	Sector	Amount (in Million EUR)	Ownership	Country
PolyPid Ltd	Biotechnology - Therapeutics and Diagnostics	19.8	Private / independent	Israel
Redwood Pharma AB	Biotechnology - Therapeutics and Diagnostics	0.7	Private / independent	Sweden
Micreos	Biotechnology - other	10.8	Private / independent	Netherlands
Saphetor SA	Biotechnology / R&D Services	1.1	Private / independent	Switzerland
Apogenix GmbH	Biotechnology - Therapeutics and Diagnostics	2.7	Private / independent	Germany
D-EYE, Srl	Medical Technology	1.5	Private / independent	Italy
MilliDrop	Biotechnology / R&D Services	1.0	Private / independent	France
MilliDrop Instruments S.A.S.	Medical Technology	1.0	Private / independent	France
Hemovent GmbH	Medical Technology	5.4	Private / independent	Germany
Via Surgical Ltd.	Medical Technology	5.4	Private / independent	Israel
ENYO Pharma SAS	Biotechnology - Therapeutics and Diagnostics	22.0	Private / independent	France
Confo Therapeutics	Biotechnology - Therapeutics and Diagnostics	6.0	Private / independent	Belgium
Cuquantum Medical Cosmetics	Biotechnology - other	1.6	Private / independent	Spain
GoodGut	Biotechnology / R&D Services	0.6	Private / independent	Spain
Synoste Ltd	Medical Technology	1.0	Private / independent	Finland
vasopharm GmbH	Biotechnology - Therapeutics and Diagnostics	20.0	Private / independent	Germany
Abviris	Medical Technology	0.1	Private / independent	Germany
Glactone Pharma AB	Biotechnology - Therapeutics and Diagnostics	U.D.	Private / independent	Sweden
NovImmune SA	Biotechnology - Therapeutics and Diagnostics	27.4	Private / independent	Switzerland



Cardiorentis AG	Biotechnology - Therapeutics and Diagnostics	54.9	Private / independent	Switzerland
V-Wave Ltd.	Medical Technology	25.8	Private / independent	Israel
CartiHeal	Medical Technology	13.8	Private / independent	Israel
Aelix Therapeutics	Biotechnology - Therapeutics and Diagnostics	11.7	Private / independent	Spain
Corion Biotech	Biotechnology / R&D Services	4.0	Private / independent	Italy
Aurealis Pharma Ltd.	Biotechnology - Therapeutics and Diagnostics	3.0	Private / independent	Finland
Pi-Cardia Ltd.	Medical Technology	9.2	Private / independent	Israel
Prothena Corporation plc	Biotechnology - Therapeutics and Diagnostics	102.9	Public listed on stock exchange	Ireland
Neovacs S. A.	Biotechnology - Therapeutics and Diagnostics	5.0	Publicly listed on stock exchange	France
IO Biotech ApS	Biotechnology - Therapeutics and Diagnostics	11.0	Private / independent	Denmark
AB-Biotics	Biotechnology - other	0.6	Private / independent	Spain
ViroVet BVBA	Biotechnology - Therapeutics and Diagnostics	U.D.	Private / independent	Belgium
Emperra GmbH E-Health Technologies	Medical Technology	2.9	Private / independent	Germany

UD: undisclosed



## About this summary

The Life Sciences Financing Summary is published on a bi-monthly basis by Venture Valuation and Fit for Health 2.0 and can be downloaded for free either from our newsletter or from the website <http://www.fitforhealth.eu/>

The data used for this summary is taken from Venture Valuation's global Biotech and life science database Biotechgate. Biotechgate is a popular source for life sciences company and licensing deals information. If you are interested in learning more, please do not hesitate to contact us and to apply for a trial.

[Click here to learn more about Biotechgate »](#)

Venture Valuation  
Kasernenstrasse 11  
8004 Zurich  
Switzerland

Phone: +41 (43) 321 86 60

Web: [www.venturevaluation.com](http://www.venturevaluation.com)

Copyright © 2016 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebitech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at [www.biotechgate.com](http://www.biotechgate.com)

Email: [info@venturevaluation.com](mailto:info@venturevaluation.com)